CG0070 Adenovirus Vector
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transitional Cell Carcinoma
Conditions
Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ, Carcinoma in Situ Concurrent With Papillary Tumors
Trial Timeline
Mar 1, 2014 → Jun 1, 2016
NCT ID
NCT01438112About CG0070 Adenovirus Vector
CG0070 Adenovirus Vector is a phase 2/3 stage product being developed by CG Oncology for Transitional Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01438112. Target conditions include Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01438112 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Transitional Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab vedotin | Astellas Pharma | Phase 2 | 52 |
| enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine | Astellas Pharma | Phase 1/2 | 41 |
| Pemetrexed + Gemcitabine + Platinol | Eli Lilly | Phase 1/2 | 41 |
| Vepugratinib + EV + Pembrolizumab | Eli Lilly | Phase 3 | 77 |
| durvalumab and tremelimumab | AstraZeneca | Phase 2 | 52 |
| Docetaxel + vandetanib + Placebo | AstraZeneca | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Everolimus + Everolimus + Paclitaxel | Novartis | Phase 2 | 52 |
| Buparlisib | Novartis | Phase 2 | 52 |
| BEZ235 | Novartis | Phase 2 | 52 |
| Atezolizumab | Roche | Phase 3 | 77 |
| Gemcitabine + Cisplatin + Sunitinib Malate | Pfizer | Phase 2 | 51 |
| Nivolumab/Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| vinflunine and best supportive care | Bristol Myers Squibb | Phase 3 | 76 |
| vinflunine | Bristol Myers Squibb | Phase 2 | 51 |
| Dasatinib | Bristol Myers Squibb | Pre-clinical | 22 |
| Docetaxel + Oxaliplatin | Sanofi | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2/3 | 64 |
| Rogaratinib (BAY1163877) + Chemotherapy | Bayer | Phase 2/3 | 62 |